Cargando…

Characterizing the cytoprotective activity of Sarracenia purpurea L., a medicinal plant that inhibits glucotoxicity in PC12 cells

BACKGROUND: The purple pitcher plant, Sarracenia purpurea L., is a widely distributed species in North America with a history of use as both a marketed pain therapy and a traditional medicine in many aboriginal communities. Among the Cree of Eeyou Istchee in northern Québec, the plant is employed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Harris, Cory S, Asim, Muhammad, Saleem, Ammar, Haddad, Pierre S, Arnason, John T, Bennett, Steffany AL
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556504/
https://www.ncbi.nlm.nih.gov/pubmed/23216659
http://dx.doi.org/10.1186/1472-6882-12-245
_version_ 1782257193199861760
author Harris, Cory S
Asim, Muhammad
Saleem, Ammar
Haddad, Pierre S
Arnason, John T
Bennett, Steffany AL
author_facet Harris, Cory S
Asim, Muhammad
Saleem, Ammar
Haddad, Pierre S
Arnason, John T
Bennett, Steffany AL
author_sort Harris, Cory S
collection PubMed
description BACKGROUND: The purple pitcher plant, Sarracenia purpurea L., is a widely distributed species in North America with a history of use as both a marketed pain therapy and a traditional medicine in many aboriginal communities. Among the Cree of Eeyou Istchee in northern Québec, the plant is employed to treat symptoms of diabetes and the leaf extract demonstrates multiple anti-diabetic activities including cytoprotection in an in vitro model of diabetic neuropathy. The current study aimed to further investigate this activity by identifying the plant parts and secondary metabolites that contribute to these cytoprotective effects. METHODS: Ethanolic extracts of S. purpurea leaves and roots were separately administered to PC12 cells exposed to glucose toxicity with subsequent assessment by two cell viability assays. Assay-guided fractionation of the active extract and fractions was then conducted to identify active principles. Using high pressure liquid chromatography together with mass spectrometry, the presence of identified actives in both leaf and root extracts were determined. RESULTS: The leaf extract, but not that of the root, prevented glucose-mediated cell loss in a concentration-dependent manner. Several fractions elicited protective effects, indicative of multiple active metabolites, and, following subfractionation of the polar fraction, hyperoside (quercetin-3-O-galactoside) and morroniside were isolated as active constituents. Phytochemical analysis confirmed the presence of hyperoside in the leaf but not root extract and, although morroniside was detected in both organs, its concentration was seven times higher in the leaf. CONCLUSION: Our results not only support further study into the therapeutic potential and safety of S. purpurea as an alternative and complementary treatment for diabetic complications associated with glucose toxicity but also identify active principles that can be used for purposes of standardization and quality control.
format Online
Article
Text
id pubmed-3556504
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35565042013-01-29 Characterizing the cytoprotective activity of Sarracenia purpurea L., a medicinal plant that inhibits glucotoxicity in PC12 cells Harris, Cory S Asim, Muhammad Saleem, Ammar Haddad, Pierre S Arnason, John T Bennett, Steffany AL BMC Complement Altern Med Research Article BACKGROUND: The purple pitcher plant, Sarracenia purpurea L., is a widely distributed species in North America with a history of use as both a marketed pain therapy and a traditional medicine in many aboriginal communities. Among the Cree of Eeyou Istchee in northern Québec, the plant is employed to treat symptoms of diabetes and the leaf extract demonstrates multiple anti-diabetic activities including cytoprotection in an in vitro model of diabetic neuropathy. The current study aimed to further investigate this activity by identifying the plant parts and secondary metabolites that contribute to these cytoprotective effects. METHODS: Ethanolic extracts of S. purpurea leaves and roots were separately administered to PC12 cells exposed to glucose toxicity with subsequent assessment by two cell viability assays. Assay-guided fractionation of the active extract and fractions was then conducted to identify active principles. Using high pressure liquid chromatography together with mass spectrometry, the presence of identified actives in both leaf and root extracts were determined. RESULTS: The leaf extract, but not that of the root, prevented glucose-mediated cell loss in a concentration-dependent manner. Several fractions elicited protective effects, indicative of multiple active metabolites, and, following subfractionation of the polar fraction, hyperoside (quercetin-3-O-galactoside) and morroniside were isolated as active constituents. Phytochemical analysis confirmed the presence of hyperoside in the leaf but not root extract and, although morroniside was detected in both organs, its concentration was seven times higher in the leaf. CONCLUSION: Our results not only support further study into the therapeutic potential and safety of S. purpurea as an alternative and complementary treatment for diabetic complications associated with glucose toxicity but also identify active principles that can be used for purposes of standardization and quality control. BioMed Central 2012-12-05 /pmc/articles/PMC3556504/ /pubmed/23216659 http://dx.doi.org/10.1186/1472-6882-12-245 Text en Copyright ©2012 Harris et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Harris, Cory S
Asim, Muhammad
Saleem, Ammar
Haddad, Pierre S
Arnason, John T
Bennett, Steffany AL
Characterizing the cytoprotective activity of Sarracenia purpurea L., a medicinal plant that inhibits glucotoxicity in PC12 cells
title Characterizing the cytoprotective activity of Sarracenia purpurea L., a medicinal plant that inhibits glucotoxicity in PC12 cells
title_full Characterizing the cytoprotective activity of Sarracenia purpurea L., a medicinal plant that inhibits glucotoxicity in PC12 cells
title_fullStr Characterizing the cytoprotective activity of Sarracenia purpurea L., a medicinal plant that inhibits glucotoxicity in PC12 cells
title_full_unstemmed Characterizing the cytoprotective activity of Sarracenia purpurea L., a medicinal plant that inhibits glucotoxicity in PC12 cells
title_short Characterizing the cytoprotective activity of Sarracenia purpurea L., a medicinal plant that inhibits glucotoxicity in PC12 cells
title_sort characterizing the cytoprotective activity of sarracenia purpurea l., a medicinal plant that inhibits glucotoxicity in pc12 cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3556504/
https://www.ncbi.nlm.nih.gov/pubmed/23216659
http://dx.doi.org/10.1186/1472-6882-12-245
work_keys_str_mv AT harriscorys characterizingthecytoprotectiveactivityofsarraceniapurpurealamedicinalplantthatinhibitsglucotoxicityinpc12cells
AT asimmuhammad characterizingthecytoprotectiveactivityofsarraceniapurpurealamedicinalplantthatinhibitsglucotoxicityinpc12cells
AT saleemammar characterizingthecytoprotectiveactivityofsarraceniapurpurealamedicinalplantthatinhibitsglucotoxicityinpc12cells
AT haddadpierres characterizingthecytoprotectiveactivityofsarraceniapurpurealamedicinalplantthatinhibitsglucotoxicityinpc12cells
AT arnasonjohnt characterizingthecytoprotectiveactivityofsarraceniapurpurealamedicinalplantthatinhibitsglucotoxicityinpc12cells
AT bennettsteffanyal characterizingthecytoprotectiveactivityofsarraceniapurpurealamedicinalplantthatinhibitsglucotoxicityinpc12cells